triazoles has been researched along with Liver Diseases in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.51) | 18.7374 |
| 1990's | 5 (10.64) | 18.2507 |
| 2000's | 22 (46.81) | 29.6817 |
| 2010's | 16 (34.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bábíčková, J; Borbélyová, V; Celec, P; Domonkos, E; Hodosy, J; Kačmárová, M; Ostatníková, D; Tóthová, Ľ; Uličná, O | 1 |
| Ding, H; Fang, L; Huang, P; Sun, J; Tong, Y; Xu, G; Zhang, Y; Zheng, X; Zhu, L | 1 |
| Marini, BL; Perissinotti, AJ | 1 |
| Abrams, TA; Blaszkowsky, LS; Chen, J; Goyal, L; Karol, MD; McCleary, NJ; Sheehan, S; Sundaram, E; Wadlow, RC; Wolpin, BM; Zhu, AX | 1 |
| Cai, KQ; Egleston, BL; Golemis, EA; Hensley, HH; Nikonova, AS; Proia, DA; Seeger-Nukpezah, T; Smithline, ZB | 1 |
| Ciric, S; Fernandes, P; Jamieson, BD | 1 |
| Carbonari, DM; Corley, DA; Forde, KA; Goldberg, DS; Haynes, K; Lewis, JD; Lo Re, V; Marks, AR; Reddy, KR; Roy, JA; Schneider, JL; Sha, D; Strom, BL | 1 |
| Desai, A; Mujais, S; Schmitt-Hoffmann, AH; Townsend, R | 1 |
| Bernardo, RM; Gurung, A; Jain, D; Malinis, MF | 1 |
| Auger, P; Fan, L; Iwamoto, M; Khalilieh, S; Lasseter, KC; Liu, R; Marbury, T; Sanchez, RI; Stypinski, D; Triantafyllou, I; Yee, KL | 1 |
| Boonprasert, R; Chayakulkeeree, M; Dilokpattanamongkol, P; Panusitthikorn, P; Rotjanapan, P | 1 |
| Codl, D; Laznickova, T; Malaskova, L; Masova, I; Nyc, O; Sedlacek, P; Stary, J; Vavra, V | 1 |
| Alffenaar, JW; Daenen, SM; de Vos, T; Uges, DR | 1 |
| Aebi, C; Berger, S; Diepold, M; Duppenthaler, A; Lüer, S; Mühlethaler, K; von Gunten, M; Wolf, R | 1 |
| Poveda, E; Soriano, V | 1 |
| Hangaishi, A; Imai, Y; Kumano, K; Kurokawa, M; Nannya, Y; Takahashi, T; Ueda, K | 1 |
| Dix, DJ; Goetz, AK | 1 |
| Ackerman, Z; Avraham, Y; Berry, EM; Magen, I; Mechoulam, R; Vorobiev, L | 1 |
| Edwards, DJ; Heep, M; Peterfaí, E; Roos, B; Schmitt-Hoffmann, A; Spickermann, J; Stoeckel, K | 1 |
| Abel, S; Davis, JD; Hamlin, JC; Ridgway, CE; Vourvahis, M | 1 |
| Corey, M | 1 |
| Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC | 1 |
| Falcone, M; Massetti, AP; Russo, A; Venditti, M; Vullo, V | 1 |
| Hamada, Y; Kuroyama, M; Seto, Y; Yago, K | 1 |
| Abboud, CS; Baía, CE; Bergamasco, MD; Lallée, MP; Mies, S; Pereira, OI; Zamorano, MM; Zan, AS | 1 |
| Barberán, J; Carreras, E; Jarque, I; Mensa, J; Serrano, D; Vázquez, L | 1 |
| Ullmann, AJ | 1 |
| Day, YJ; Huang, L; Linden, J; Marshall, MA; McDuffie, MJ; Okusa, MD | 1 |
| Arango, M; Correa, AL; de Bedout, C; Restrepo, A; Tobón, AM | 1 |
| Blijlevens, NM; Donnelly, JP; Klont, RR; van der Velden, WJ; Verweij, PE | 1 |
| Bujanda, L; Piérola, A; Zapata, E; Zubiaurre, L | 1 |
| Lambert, JS; Poulton, MB; Scott, CJ; Taylor, CB | 1 |
| Krause, DS | 1 |
| Dubarek, W; Kucia, K | 1 |
| Brissot, P; Deugnier, Y; Loréal, O | 1 |
| Cloyd, J; Critchley, D; Fuseau, E; Perucca, E | 1 |
| Gearhart, MO | 1 |
| Bernard, N; Cuisinaud, G; Ferry, N; Rougier, P; Sassard, J; Trepo, C | 1 |
| Andriole, VT; George, D; Miniter, P | 1 |
| Bailie, MB; Fink, GD; Pearson, JM; Roth, RA | 1 |
| Barbhaiya, RH; Greene, DS | 1 |
| Girija, R; Hwang, YK; Joo, NH; Tan, L; Tan, P; Tee, GY | 1 |
| Carvajal García-Pando, A; García del Pozo, J; Lucena, MI; Rueda de Castro, AM; Sánchez, AS; Velasco, MA | 1 |
| Inatsu, Y; Ishii, H; Ninobe, S; Suga, T | 1 |
| Knobel, M | 2 |
| Johnson, EA; Stenger, RJ | 1 |
10 review(s) available for triazoles and Liver Diseases
| Article | Year |
|---|---|
Therapeutic Challenges of Hepatic Mucormycosis in Hematologic Malignancy: A Case Report and Review of the Literature.
Topics: Amphotericin B; Antifungal Agents; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Liver Diseases; Middle Aged; Mucormycosis; Risk Factors; Treatment Failure; Treatment Outcome; Triazoles | 2016 |
[Pharmacokinetics, interactions and mechanism of action of maraviroc].
Topics: Adolescent; Adult; Aged; Biological Availability; Biotransformation; CCR5 Receptor Antagonists; Chemokines, CC; Clinical Trials as Topic; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Interactions; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Kidney Diseases; Liver Diseases; Maraviroc; Membrane Fusion; Receptors, CCR5; Triazoles; Virus Attachment; Virus Internalization; Virus Replication | 2008 |
Modern antifungal therapy for neutropenic fever.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Echinocandins; Fever; Humans; Immunocompromised Host; Kidney Diseases; Lipopeptides; Liposomes; Liver Diseases; Mycoses; Neutropenia; Pyrimidines; Triazoles; Voriconazole | 2006 |
Invasive aspergillosis in patients with liver disease.
Topics: Aged; Antifungal Agents; Aspergillosis; Caspofungin; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Liver Diseases; Lung; Male; Middle Aged; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2011 |
Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
Topics: Age Factors; Antifungal Agents; Drug Monitoring; Female; Humans; Liver Diseases; Male; Mycoses; Odds Ratio; Pyrimidines; Triazoles; Voriconazole | 2012 |
Pharmacological aspects of the new triazole voriconazole.
Topics: Antifungal Agents; Contraindications; Drug Interactions; Humans; Kidney Diseases; Liver Diseases; Pyrimidines; Triazoles; Voriconazole | 2002 |
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Depressive Disorder; Humans; Liver Diseases; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Risk Factors; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 2007 |
Iron and the liver: update 2008.
Topics: Antimicrobial Cationic Peptides; Benzoates; Deferasirox; Hemochromatosis; Hepcidins; Homeostasis; Humans; Iron; Iron Chelating Agents; Liver; Liver Diseases; Triazoles | 2008 |
Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity.
Topics: Administration, Oral; Alanine Transaminase; Aspartate Aminotransferases; Candidiasis; Chemical and Drug Induced Liver Injury; Female; Fluconazole; Hospitals, Teaching; Humans; Liver Diseases; Liver Function Tests; Middle Aged; Triazoles; Urinary Tract Infections | 1994 |
Clinical pharmacokinetics of nefazodone.
Topics: Adult; Age Factors; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Female; Humans; Kidney Diseases; Liver Diseases; Male; Piperazines; Sex Factors; Triazoles | 1997 |
9 trial(s) available for triazoles and Liver Diseases
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; HSP90 Heat-Shock Proteins; Humans; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Treatment Outcome; Triazoles | 2015 |
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.
Topics: Administration, Oral; Female; Healthy Volunteers; Humans; Liver; Liver Diseases; Male; Models, Theoretical; Nitriles; Pyridines; Triazoles | 2016 |
Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
Topics: Adult; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2017 |
Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.
Topics: Administration, Oral; Antifungal Agents; Area Under Curve; Female; Humans; Injections, Intravenous; Liver Diseases; Male; Middle Aged; Nitriles; Prodrugs; Pyridines; Triazoles | 2009 |
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Topics: Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Administration Schedule; Female; Humans; Liver Diseases; Male; Maraviroc; Middle Aged; Triazoles | 2009 |
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles | 2010 |
Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses.
Topics: Adolescent; Adult; Antidepressive Agents; Female; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Triazoles | 1994 |
Trazodone and psychosomatic medicine.
Topics: Adult; Antidepressive Agents; Biliary Tract Diseases; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gastrointestinal Diseases; Genital Diseases, Female; Genital Diseases, Male; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychophysiologic Disorders; Pyridines; Respiratory Tract Diseases; Triazoles; Urologic Diseases | 1973 |
The use of trazodone in psychosomatic medicine.
Topics: Adult; Antidepressive Agents; Asthma; Biliary Tract Diseases; Clinical Trials as Topic; Colitis; Coronary Disease; Depression; Female; Gastritis; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Placebos; Psychophysiologic Disorders; Pyridines; Triazoles; Urologic Diseases | 1974 |
28 other study(ies) available for triazoles and Liver Diseases
| Article | Year |
|---|---|
Does long-term androgen deficiency lead to metabolic syndrome in middle-aged rats?
Topics: Age Factors; Andropause; Animals; Aromatase Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Disease Models, Animal; Estradiol; Female; Hormone Replacement Therapy; Hypogonadism; Letrozole; Liver; Liver Diseases; Male; Metabolic Syndrome; Nitriles; Orchiectomy; Ovariectomy; Rats, Inbred Lew; Sex Factors; Sexual Development; Testosterone; Triazoles; Uric Acid | 2017 |
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Topics: Antifungal Agents; Area Under Curve; Aspergillus; Candida; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Liver Diseases; Male; Microbial Sensitivity Tests; Monte Carlo Method; Nitriles; Pyridines; Renal Insufficiency; Species Specificity; Triazoles | 2018 |
Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?
Topics: Adult; Aged; Antifungal Agents; Chemoprevention; Drug Substitution; Female; Humans; Leukemia, Myeloid, Acute; Liver Diseases; Liver Function Tests; Male; Middle Aged; Mycoses; Retrospective Studies; Time Factors; Triazoles; Young Adult | 2019 |
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Topics: Animals; Cysts; Female; Gene Knockout Techniques; HSP90 Heat-Shock Proteins; Liver; Liver Diseases; Male; Mice, Knockout; Protein Kinase C; Resorcinols; Triazoles | 2014 |
Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.
Topics: Adult; Aged; Area Under Curve; Body Mass Index; Case-Control Studies; Female; Humans; Liver; Liver Diseases; Macrolides; Male; Middle Aged; Triazoles | 2015 |
Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
Topics: Administration, Oral; Adult; Antifungal Agents; California; Chemical and Drug Induced Liver Injury; Chronic Disease; Cohort Studies; Female; Humans; Liver Diseases; Liver Failure, Acute; Male; Middle Aged; Retrospective Studies; Transaminases; Triazoles | 2016 |
A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.
Topics: Administration, Intravenous; Adult; Antifungal Agents; Aspergillus; Drug Monitoring; Fatal Outcome; Humans; Invasive Pulmonary Aspergillosis; Kidney Diseases; Liver Diseases; Male; Triazoles | 2017 |
Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Humans; Infant; Leukemia, Myeloid, Acute; Liver; Liver Diseases; Male; Mycetoma; Rhizopus; Triazoles | 2009 |
High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?
Topics: Antifungal Agents; Humans; Liver Diseases; Pyrimidines; Triazoles; Voriconazole | 2009 |
Treatment of intestinal and hepatic mucormycosis in an immunocompromized child.
Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Child, Preschool; Drug Therapy, Combination; Humans; Immunocompromised Host; Intestinal Diseases; Liver Diseases; Magnetic Resonance Imaging; Male; Mucormycosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Tomography, X-Ray Computed; Triazoles; Vincristine | 2009 |
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Dose-Response Relationship, Drug; Drug Monitoring; Hematologic Neoplasms; Humans; Liver Diseases; Male; Middle Aged; Mycoses; Pyrimidines; Triazoles; Voriconazole; Young Adult | 2009 |
Mode of action for reproductive and hepatic toxicity inferred from a genomic study of triazole antifungals.
Topics: Aging; Animals; Antifungal Agents; Chemical and Drug Induced Liver Injury; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Gestational Age; Infertility, Male; Liver; Liver Diseases; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Rats; Rats, Wistar; Reproduction; Testis; Testosterone; Triazoles | 2009 |
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.
Topics: Adenosine A2 Receptor Antagonists; Animals; Bile Ducts; Brain-Derived Neurotrophic Factor; Cannabidiol; Chronic Disease; Cognition; Cognition Disorders; Cyclooxygenase 2; Disease Models, Animal; Female; Gait Disorders, Neurologic; Hepatic Encephalopathy; Ligation; Liver Diseases; Mice; Mice, Inbred Strains; Motor Activity; Receptor, Adenosine A2A; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Treatment Outcome; Triazines; Triazoles | 2009 |
Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy.
Topics: Amphotericin B; Antifungal Agents; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Liver Diseases; Liver Transplantation; Mucormycosis; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2012 |
Antifungal prophylaxis in the haematological patient: a practical approach.
Topics: Algorithms; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Biological Availability; Decision Trees; Drug Interactions; Echinocandins; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Diseases; Mycoses; Myelodysplastic Syndromes; Postoperative Complications; Practice Guidelines as Topic; Premedication; Triazoles | 2012 |
Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction.
Topics: Adenosine A2 Receptor Agonists; Animals; Blood Cells; Chemokines; Cyclohexanecarboxylic Acids; Cytokines; Drug Administration Schedule; Edema; Gene Deletion; Ischemia; Leukocytes; Liver; Liver Circulation; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Purines; Radioligand Assay; Receptor, Adenosine A2A; Reperfusion Injury; RNA, Messenger; Triazines; Triazoles | 2004 |
Posaconazole therapy for severe abdominal candidiasis: a case report.
Topics: Abdomen; Aged; Antifungal Agents; Candidiasis; Cysts; Female; Humans; Liver Diseases; Postoperative Complications; Severity of Illness Index; Triazoles | 2004 |
Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Galactose; Graft vs Host Disease; Humans; Liver Diseases; Lymphoproliferative Disorders; Mannans; Middle Aged; Pyrimidines; Rituximab; Splenic Diseases; Stem Cell Transplantation; Transplantation, Homologous; Triazoles; Voriconazole | 2006 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases; Liver Function Tests; Nausea; Nitriles; Triazoles | 2006 |
Invasive Aspergillus fumigatus associated with liver and bone involvement in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Bone Diseases; Humans; Liver Diseases; Male; Pyrimidines; Triazoles; Voriconazole | 2007 |
Posaconazole prophylaxis in hematologic cancer.
Topics: Antifungal Agents; Bilirubin; Chemical and Drug Induced Liver Injury; Fluconazole; Graft vs Host Disease; Humans; Liver Diseases; Mycoses; Transaminases; Triazoles | 2007 |
Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Topics: Administration, Oral; Adolescent; Age Factors; Anticonvulsants; Body Mass Index; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Epilepsy; Female; Food; Half-Life; Humans; Intrinsic Factor; Kidney Diseases; Liver Diseases; Male; Metabolic Clearance Rate; Renal Dialysis; Sex Factors; Syndrome; Triazoles | 2008 |
Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
Topics: Animals; Antifungal Agents; Antigens, Fungal; Aspergillosis; Aspergillus fumigatus; Azoles; Female; Kidney Diseases; Liver Diseases; Lung Diseases, Fungal; Pyrimidines; Rabbits; Triazoles; Voriconazole | 1996 |
Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Topics: Administration, Oral; Alanine Transaminase; Animals; Azepines; Blood Platelets; Chemical and Drug Induced Liver Injury; Female; Fibrinogen; Hydroxyurea; Injections, Intraperitoneal; Injections, Intravenous; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Liver; Liver Diseases; Necrosis; Neutrophils; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thrombocytopenia; Triazoles | 1997 |
Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia.
Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Child; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Liver Diseases; Male; Pyrimidines; Splenic Diseases; Triazoles; Voriconazole | 2001 |
Hepatotoxicity associated with the new antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Drug Monitoring; Female; Humans; Incidence; Liver Diseases; Piperazines; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Triazoles | 2002 |
Effect of 3-amino-1,2,4-triazole on carbon tetrachloride-induced necrosis.
Topics: Alanine Transaminase; Amitrole; Animals; Aspartate Aminotransferases; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Depression, Chemical; Liver Diseases; Male; Necrosis; Rats; Triazoles | 1977 |
Modifying effect of 3-amino-1,2,4-triazole on phenobarbital-induced changes in rat liver.
Topics: Amitrole; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Cytochromes; Drug Antagonism; Endoplasmic Reticulum; Enzyme Induction; Herbicides; Liver; Liver Diseases; Male; Microscopy, Electron; Microsomes, Liver; Necrosis; Paralysis; Phenobarbital; Rats; Triazoles; Zoxazolamine | 1972 |